CD3 antibody and pharmaceutical use thereof
US12258405B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Dec 6, 2019 |
| Grant date | Mar 25, 2025 |
| Priority date | — |
| Expiry date | Jul 18, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a CD3 antibody and a pharmaceutical use thereof. Specifically, the present disclosure relates to forming a multi-specificity antibody by using CD3 antibody and binding molecules of another target. The multi-specificity antibody may simultaneously bind to CD3 and another tumor-associated antigen, and bind and activate CD3-positive T cells while binding tumor-associated antigen-expressing cells, thereby promoting T cells specifically killing tumor cells that express tumor-associated antigens. In addition, the present disclosure also provides a preparation and application of a multi-specific antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.